Comments
Granules India Limited has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Penicillamine Capsules. It is bioequivalent to the reference listed drug product (RLD), Cuprimine of Bausch Health Americas, Inc.
The product would be manufactured at Granules manufacturing facility in Chantilly, Virginia and is expected to be launched shortly, the Hyderabad-based company said in a release.
Penicillamine Capsules are indicated in the treatment of Wilson’s disease, cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy.
Granules now has a total of 35 ANDA approvals from USFDA (33 final approvals and 2 tentative approvals).
Penicillamine Capsules had US sales of approximately $67 million for the most recent twelve months ending in October 2020 according to IQVIA Health. Cuprimine is a trademark of Bausch Health Companies Inc. or its affiliates.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.